Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics, Inc. (RAPT) EBIT Margin (2020 - 2022)

RAPT Therapeutics (RAPT) has disclosed EBIT Margin for 3 consecutive years, with 2134.2% as the latest value for Q2 2022.

  • Quarterly EBIT Margin fell 28368.0% to 2134.2% in Q2 2022 from the year-ago period, while the trailing twelve-month figure was 10900.68% through Mar 2023, down 862886.0% year-over-year, with the annual reading at 5618.53% for FY2022, 380345.0% down from the prior year.
  • EBIT Margin hit 2134.2% in Q2 2022 for RAPT Therapeutics, up from 3241.34% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 954.25% in Q3 2020 to a low of 3241.34% in Q1 2022.
  • Historically, EBIT Margin has averaged 1721.86% across 3 years, with a median of 1622.42% in 2021.
  • Biggest five-year swings in EBIT Margin: skyrocketed 3909bps in 2021 and later plummeted -188610bps in 2022.
  • Year by year, EBIT Margin stood at 1004.99% in 2020, then crashed by -137bps to 2385.45% in 2021, then increased by 11bps to 2134.2% in 2022.
  • Business Quant data shows EBIT Margin for RAPT at 2134.2% in Q2 2022, 3241.34% in Q1 2022, and 2385.45% in Q4 2021.